Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb trial of 24‑valent pneumococcal conjugate vaccine in adults ≥65 years
CTR20254591Phase 2Active
- Sponsor
- 江苏坤力生物制药有限责任公司；山东坤力生物制药有限责任公司/ 江苏坤力生物制药有限责任公司
- Start
- Nov 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Reinovax PCV24 in invasive pneumococcal disease (IPD), sponsored by 江苏坤力生物制药有限责任公司；山东坤力生物制药有限责任公司/ 江苏坤力生物制药有限责任公司. Started Nov 2025; status: active.
02
Drugs
Reinovax PCV24
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on CTR20254591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254591.